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Cardiovascular Topics
Pulmonary hypertension as seen in a rural area in 
sub-Saharan Africa: high prevalence, late clinical 
presentation and a high short-term mortality rate during 
follow up
Anastase Dzudie, Bonaventure Suiru Dzekem, Cabral Tantchou Tchoumi, Leopold Ndemnge Aminde, 
Ana O Mocumbi, Martin Abanda, Friedrich Thienemann, Andre Pascal Kengne, Karen Sliwa
Abstract
Introduction: The epidemiology of pulmonary hypertension 
(PH) in low- to middle-income countries is poorly character-
ised. We assessed the prevalence, baseline characteristics and 
mortality rate in patients with echocardiographically diag-
nosed PH at a rural cardiac centre in Cameroon.
Methods: We conducted a prospective cohort study in a sub-
sample of 150 participants, aged 18 years and older, diag-
nosed with PH [defined as right ventricular systolic pressure 
(RVSP) ≥ 35 mmHg in the absence of pulmonary stenosis and 
right heart failure]. PH was classified as mild (RVSP: 35–50 
mmHg), moderate (RVSP: 51–60 mmHg) and severe (RVSP: 
> 60 mmHg).
Results: Of 2 194 patients screened via echocardiograms, 
343 (crude prevalence 15.6%) had PH. The sub-sample of 
150 patients followed up (54.7% women, mean age of 62.7 ± 
18.7 years) had a mean RVSP of 68.6 mmHg. They included 
7.3% mild, 29.3% moderate and 63.4% severe PH cases. 
Co-morbidities included log smoke (80.7%), hypertension  
(52.0%), family history of cardiovascular disease (50.0%), 
diabetes (31.3%), alcohol abuse (21.3%) and HIV infection 
(8.7%). Main clinical features were dyspnoea (78.7%), fatigue 
(76.7%), palpitations (57.3%), cough (56.7%), jugular venous 
distension (68%) and peripheral oedema (66.7%). Overall, 
70% presented in World Health Organisation functional 
class III/IV. PH due to left heart disease (PHLHD) was the 
commonest (64.7%), and rheumatic valvular disease account-
ed for 36.1%. The six-month mortality rate was 28%. 
Conclusion: PH, dominated by PHLHD, was common among 
adults attending this rural centre and was associated with 
a high mortality rate. Related co-morbidities and late clini-
cal presentation reflect the poor socio-economic context. 
Improved awareness of PH among physicians could promote 
early diagnosis and management.
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Pulmonary hypertension (PH) is defined as an increase in mean 
pulmonary arterial pressure (mPAP) at or above 25 mmHg at 
rest.1,2 It is currently classified by the World Health Organisation 
(WHO) into five subtypes, which include pulmonary arterial 
hypertension (PAH), PH due to left heart disease (PHLHD), 
PH due to lung disease or hypoxia (PHLDH), chronic 
thromboembolic PH (CTEPH) and PH due to unclear or 
multifactorial mechanisms (PHUM).3,4
The prevalence of  pulmonary vascular disease in the 
developing world is unknown, but estimates suggest that about 
25 million individuals may be affected.5 Little information exists 
on the epidemiology of PH in sub-Saharan Africa, however 
there is some evidence that based on the high prevalence of risk 
factors such as rheumatic heart disease, schistosomiasis and HIV 
infection in this area of the world, the prevalence and mortality 
rate of PH may be higher than in Western countries.6,7
In South Africa, PH has been identified as one of the 
commonest causes of death, accounting for 31% of total 
cardiovascular deaths,8 while only 8% of  cardiovascular 
deaths in the United Kingdom were attributed to PH in 2012.9 
Furthermore, studies from the United States have shown that 
the prevalence of PH among African Americans is higher than 
in Caucasians.10 These differences in the epidemiology of PH 
in different regions of the world are determined by genetic, 
geographic, environmental and socio-economic factors. 
Left heart disease has been widely suggested to be the 
most common cause of PH. In developing countries, chronic 
infectious diseases, hypertensive heart diseases, cardiomyopathy 
and rheumatic heart disease are the main contributors.6 This 
study aimed at determining the prevalence, baseline clinical 
characteristics and mortality rate during six months of follow up 
of patients with PH diagnosed via echocardiography at the rural 
Shisong Cardiac Centre (SCC) in Cameroon. 
Methods
This was a prospective cohort study in a sub-sample of 150 
participants aged 18 years and older who were diagnosed with PH 
via echocardiography. It was conducted at the Shisong Cardiac 
Centre from September 2013 to December 2014. This study also 
forms part of the Pan-African Pulmonary Hypertension Cohort 
study (PAPUCO). 
Shisong is a rural village in the Kumbo sub-division of the 
north-west region of Cameroon. Shisong, on the outskirts of 
Kumbo town, is about 400 km north of Douala, the economic 
capital of Cameroon, and 450 km north-west of Yaoundé, 
the political capital of  Cameroon.11 The Shisong Cardiac 
Centre (SCC) is a well-equipped centre for the diagnosis and 
management of a variety of cardio-surgical conditions including 
PH. On average 185 echocardiographic examinations are done 
per month. In this study, the target population was restricted 
to patients living in rural or sub-urban areas, aged 18 years and 
above, who underwent echocardiographic examination at the 
centre between September 2013 and December 2014.
The PAPUCO study design and procedures have been 
described in detail elsewhere.12 In brief, PH was diagnosed 
using echocardiography in patients with a right ventricular 
systolic pressure (RVSP) ≥ 35 mmHg in the absence of acute 
right heart failure (HF) and pulmonary stenosis. The data-
collection form, adapted from the PAPUCO study, was used 
to obtain patients’ information and clinical characteristics, 
including socio-demographic factors and past medical history 
[age, gender, body mass index (BMI), HIV status, family history 
of cardiovascular disease, systemic hypertension, dyslipidaemia, 
smoking and alcohol consumption], clinical presentation 
(dyspnoea, cough, fatigue, pedal oedema, palpitations and 
World Health Organisation functional classification). 
At six months post-baseline, patients and/or their next-of-kin 
were contacted by phone to determine their vital status. For all 
fatal outcomes, the probable cause of death was assessed through 
a verbal autopsy.
Statistical analysis
Data were analysed using SPSS® (Statistical Package for 
Social Sciences for Windows) version 20. Qualitative variables 
are summarised as frequencies and percentages. Continuous 
variables are represented as means and standard deviations, 
or median (25th to 75th percentiles). Patients were categorised 
in three groups depending on PH severity; mild if  RVSP was 
36–50 mmHg, moderate if  RVSP was 51– 60 mmHg and severe 
if  RVSP was > 60 mmHg. We used χ² to compare proportions 
and Student’s t-test or Kruskal–Wallis test to compare mean 
differences for continuous variables. Statistical significance was 
accepted at a p-value of 0.05.
Results
Out of a total of  2 194 patients who underwent cardiac 
echography at baseline, 343 had PH (prevalence rate 15.6%). 
Mean age was 61.9 ± 18.0 years and female gender (189, 55.1%) 
was predominant. As shown in Fig. 1, the peak prevalence of PH 
was noticed between 60 and 69 years (91/343, 26.5%).
Characteristics of the sub-sample followed up (n = 150) were 
similar to those of the overall PH group. The mean baseline age 
was 62.7 years [standard deviation (SD) =18.7]. Mean age did not 
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Fig. 1.  Age distribution of patients with pulmonary hyperten-
sion in the Shisong Cardiac Centre.
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vary significantly by severity of PH (p = 0.25). Most participants 
(44.7%) had primary education, 32% had secondary education 
while 15.3% had never been to school. Variations by severity 
of PH were not significant (p = 0.69). The 150 followed-up 
participants included 11 (7.3%) with mild PH, 44 (29.3%) with 
moderate PH and 95 (63.4%) with severe PH. The proportion 
of women was 54.7% overall, and 5, 20 and 57%, respectively 
among the mild, moderate and severe PH groups (p = 0.09).
The distribution of risk factors for PH and co-morbidities are 
depicted in Fig. 2. Exposure to cooking fumes (80.7%), systemic 
hypertension (52.0%), family history of cardiovascular disease 
(50.0%), mitral valve regurgitation (49.3%), diabetes (31.3%) 
and alcohol abuse (21.3%) were the most common factors and 
co-morbidities identified in our study participants. 
Dyspnoea (78.7%), fatigue (76.7%), palpitation (57.3%) and 
non-productive cough (56.7%) were the main symptoms reported 
by patients on initial presentation. Syncope (6.7%) and cyanosis 
(6.0%) were rarely reported by our patients. Most patients who 
participated in this study had distended jugular veins (68.0%) 
and peripheral oedema (66.7%). Table 1 summarises variations 
in clinical signs and symptoms with PH severity. Chest pain 
varied significantly with PH severity (p = 0.03)
Fig. 3 shows variations of the World Health Organisation 
functional class (WHO FC) according to PH severity. More 
than half (53%) of the patients presented in WHO FC III, 28% 
presented in class II, while 17 and 2% presented in class IV and I, 
respectively. Therefore a greater proportion of patients presented 
with marked functional limitation. 
The main cause of PH was left heart disease (group 2), 
accounting for 64.7% of all cases, as shown in Fig. 4. In addition, 
15.3% was due to unclear or multifactorial aetiology (group 5), 
10% due to pulmonary arterial hypertension (group 1), 8% due 
to lung disease or hypoxia (group 3), and only 2% due to chronic 
thromboembolic mechanisms (group 4). Out of 97 participants 
with PHLHD, 50.5% had left ventricular systolic dysfunction 
(heart failure with reduced ejection fraction, HFrEF: EF ≤ 50%), 
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Fig. 2.  Risk factors and co-morbidities among 150 patients 
with pulmonary hypertension followed up at the 
Shisong Cardiac Centre.
Table 1. Clinical and echocardiographic findings of adult patients with PH 
Parameters All (n = 150) Mild PH (n = 11) Moderate PH (n = 44) Severe PH (n = 95) p-value
Clinical features at presentation
Difficulty breathing (dyspnoea), n (%) 118 (78.7) 9 (7.6) 32 (27.1) 77 (65.3) 0.32
Cyanosis, n (%) 9 (6.0) 1 (11.1) 2 (22.2) 6 (66.7) 0.58
Non-productive cough, n (%) 85 (56.7) 10 (11.8) 22 (25.9) 53 (62.3) 0.14
Fatigue, n (%) 115 (76.7) 8 (7.0) 30 (26.0) 77 (67.0) 0.10
Syncope, n (%) 10 (6.7) 0 3 (30.0) 7 (70.0) 0.33
Palpitations, n (%) 86 (57.3) 8 (9.3) 28 (32.6) 50 (58.1) 0.06
Chest pain, n (%) 49 (32.7) 6 (12.2) 17 (34.7) 26 (53.1) 0.03
Distended jugular veins, n (%) 102 (68.0) 8 (7.8) 26 (25.5) 68 (66.7) 0.22
Peripheral oedema, n (%) 100 (66.7) 9 (9.0) 25 (25.0) 66 (66.0) 0.43
NYHA I and II, n (%) 45 (30.0) 3 (6.0) 19 (42.2) 23 (51.1) 0.13
NYHA III and IV, n (%) 105 (70.0) 8 (7.6) 25 (23.8) 72 (68.6) 0.13
Vital signs 
BMI (kg/m2) 26.3 (18–46.8) 23.9 (21.2–26) 26.2 (18.6–42.4) 27.1 (18–46.8) 0.03
Systolic BP (mmHg) 126 (65–250) 133 (102–190) 123 (95–235) 127 (65–250) 0.26
Diastolic BP (mmHg) 79 (45–154) 73 (58–106) 78 (60–154) 80 (45–130) 0.73
Heart rate (beats/min) 88 (52–150) 96 (80–119) 88 (52–120) 86 (56–150) 0.43
Respiratory rate (breaths/min) 23 (13–40) 22 (19–28) 22 (13–35) 23 (15–40) 0.20
O2 saturation (%) 93 (55–100) 90 (82–98) 94.5 (67–99) 91.5 (55–100) 0.37
Echographic parameters
LVEDD (mm) 53 (16–72) 36 (18–56) 50 (38–70) 55 (16–72) 0.0001
LVESD (mm) 42 (13–60) 35 (13–43) 42 (22–60) 42 (18–97) 0.003
Ejection fraction (%) 48 (20–91) 66 (32–91) 46 (32–72) 46 (20–88) 0.06
Fractional shortening (%) 23 (6–95) 49 (28–61) 29 (18–33) 21 (6–95) 0.09
TAPSE (mm) 10 (7–25) 11 (8–20) 10 (8–17) 10 (7–25) 0.70
Data are number (%) or median (IQR).
BMI = body mass index, O2 = oxygen, LVEDD = left ventricular end-diastolic diameter, LVESD = left ventricular end-systolic diameter, TAPSE = tricuspid annular 
plane systolic excursion. 
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36.1% had valvular heart disease and 13.4% had left ventricular 
diastolic dysfunction (HFpEF: EF > 50%). 
The duration of follow up of the 150 participants ranged from 
five to 180 days. After a median follow up of 90.5 days, 42 deaths 
(cumulative mortality rate of 28%) were recorded. Equivalent 
figures were five deaths (cumulative incidence 45.5%) in mild PH, 
nine deaths (cumulative incidence 20.5%) in moderate PH and 
28 deaths (cumulative incidence 29.5%) in severe PH (p = 0.28).
Discussion
Our study aimed at determining the prevalence, clinical profile 
and mortality rate from PH in a rural setting in sub-Saharan 
Africa. We noted a high prevalence of PH, late presentation to 
healthcare facilities in an advanced state of heart failure, and 
consequently a high mortality rate at six months of follow up. 
These findings could be attributed to the poor socio-economic 
status, hyper-endemicity of risk factors for PH, and limited 
availability of PH-specific drug therapies. In the PAPUCO 
study,7 which was a multinational study on the epidemiology of 
PH in Africa with recruitment centres mostly in urban areas, 
similar findings were noted. Therefore it can be said that PH still 
presents a challenge on the African continent overall and not 
only in the rural setting.
Our observed prevalence of  15.6% is higher than the 
average of 10% prevalence observed in Australia in 2012 and 
in other European countries.13 This is somewhat to be expected 
considering the high burden of risk factors such as rheumatic 
heart disease, schistosomiasis, tuberculosis, sickle cell disease 
and HIV infection in sub-Saharan Africa, in addition to other 
risk factors shared with high-income countries. In addition, 
the SCC is located in a rural area that is difficult to access. 
Therefore, patients are usually reluctant to visit the centre 
until they are in advanced disease states or when referred by 
cardiologists. A recent expert review on the global perspective 
of the epidemiology of PH also supports our findings.6 Among 
the several co-morbidities assessed in our study population, 
exposure to cooking fumes was the most common, especially in 
women. This most likely results from the common practice in 
Africa and Cameroon, particularly in the rural setting, where 
women cook using open fires, unlike in high-income countries. 
Systemic arterial hypertension was also common and in line with 
studies from Africa,7 USA14,15 and Germany.16 
Hypertension is very common in sub-Saharan Africa where 
it affects about 30% of the adult population, and mostly goes 
undetected, undertreated and inadequately controlled.17 It is the 
principal cause of HF in sub-Saharan Africa. In the Pan-African 
THESUS-HF registry of HF for instance, it was estimated that up 
to 50% of HF cases were due to uncontrolled hypertension.18This 
high prevalence of uncontrolled hypertension would most likely 
also account for the high proportion of PHLHD in our study 
population. With the growing epidemic of HF, LHD is now 
globally recognised as the main cause of PH.6,7,13 PHLHD was 
dominated by patients with left ventricular systolic dysfunction, 
while PH due to rheumatic valvular heart disease is still common 
in our setting.
The clinical presentation was dominated by exertion 
dyspnoea, fatigue, cough and palpitations, which are common 
and non-specific symptoms in most patients with cardiovascular 
and/or respiratory conditions. Study participants were slightly 
overweight with a mean BMI higher than observed in a study 
in Nigeria,19 but lower than reported in the USA.15 Most of 
our participants presented with moderate to severe functional 
limitation, with 70% of them presenting in WHO FC or New 
York Heart Association (NYHA) class III and IV. 
These findings are similar to those in the PAPUCO study,7 and 
to those of Baptista and colleagues in Portugal in 2013,20 who 
observed that 71% of their patients presented in WHO FC III 
and IV, as well as those of Fikret and colleagues in Germany.16 
This global observation of late presentation to medical attention 
could be explained by the fact that most symptoms and signs of 
PH are non-specific and therefore cases are usually misdiagnosed 
in primary care until the later stages when patients seek specialist 
care. Furthermore, in Africa, poor access to healthcare, limited 
availability of diagnostic tools for PH, and the general reluctance 
of patients in rural settings to seek medical attention until the later 
stages of illness could explain at least in part the late presentation.
About a third of our patients died within the first six months 
of being diagnosed with PH. This mortality rate is three times 
higher than that observed in the USA15 and the UK.9 The high 
mortality rate in our setting is most likely accounted for to some 
extent by the unavailability of disease-specific drug therapies. 
The fact that patients present at an advanced stage of the disease, 
and their inability to comply with follow-up visits reflects to 
some extent their limited financial coping capacity, resulting in 
death in the absence of adequate care. 
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Limitations 
Our study has some limitations. Some cases of PH could have 
been missed because indications for cardiac echocardiography 
are usually symptom driven. This would lead to over-diagnosis 
of patients with severe disease, and accordingly, poor outcomes. 
Therefore whether our finding reflects those of  a typical 
population with PH in this setting is unknown. Diagnosis 
of PH in our study was done by echocardiography, which is 
more a screening tool for PH, while right heart catheterisation 
(RHC), which is the gold standard for diagnosing PH, was 
not used. Therefore, cases of mild PH could have been missed 
in our study. Furthermore the operator-dependent nature 
of echocardiography could lead to over- or under-diagnosis. 
Despite the fact that echocardiography is only a screening tool, 
it is paramount in the diagnosis of PH as it is non-invasive, 
more available and less expensive compared to RHC. Moreover, 
in expert hands, it yields reliable and reproducible results. 
Indeed, studies carried out to evaluate the diagnostic accuracy 
of echocardiography compared to RHC have demonstrated a 
sensitivity of 83% and a specificity of 72%.21 
Conclusion
Our findings suggest that PH is very common among patients 
attending our rural cardiac centre, with PHLHD being the most 
frequent type, and the short- to medium-term mortality rate 
being excessively high. Patients tend to present in advanced stages 
of disease and usually with several co-morbidities, most of which 
are cardiovascular conditions. Healthcare practitioners in this 
setting should be made more aware of this devastating condition, 
in order to prompt timely referral to specialised centres for proper 
evaluation and care of patients with suspected PH.
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